Research Article: Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-/ Ligands in Hepatocellular Carcinoma
Introduction:
Hepatocellular carcinoma (HCC) ranks sixth in cancer incidence and fourth in cancer-related deaths. Unfortunately, many patients with HCC are diagnosed at a moderate-to-advanced stage, where treatment is limited to local or systemic therapies. The current first-line systemic treatments for HCC, such as sorafenib, lenvatinib, donafenib, and anti-PD antibodies, have limited efficacy, extending patients’ median survival by less than six months. – Given these shortcomings, there is an urgent need to explore new…
Read more